Patents by Inventor Sina Bavari

Sina Bavari has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CATHEPSIN INHIBITORS FOR PREVENTING OR TREATING VIRAL INFECTIONS
    Publication number: 20240066037
    Abstract: Provided are cathepsin inhibitor compounds and pharmaceutically acceptable salts thereof, and combinations thereof, for use in the treatment or prophylaxis of viral disease in an animal.
    Type: Application
    Filed: March 26, 2021
    Publication date: February 29, 2024
    Inventors: Sina BAVARI, Christopher D. KANE, Andrew James PEAT, Veronica SOLOVEVA
  • METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASES
    Publication number: 20230142126
    Abstract: The present disclosure relates to antiviral compositions and methods. Methods for using the antiviral compositions for inhibiting replication of viruses and treatment of viral diseases are also described. The present disclosure additionally relates to compositions and methods for enhancing a drug’s efficacy by combining the drug with a mammalian protease inhibitor such as a cathepsin inhibitor. Methods for using the combinations for treatment of disease are described.
    Type: Application
    Filed: November 15, 2022
    Publication date: May 11, 2023
    Applicant: HEALION BIO., INC.
    Inventors: Sina BAVARI, Simon NEWMAN
  • BENZONAPTHYRIDINE COMPOSITIONS AND USES THEREOF
    Publication number: 20180333406
    Abstract: The present invention generally relates to compositions comprising benzonapthyridine small molecule immune potentiators (SMIPs) that are capable of stimulating or modulating an immune response in a subject that has had pre- or post-exposure to a pathogen such as hemorrhagic fever virus. Also provided are methods of preparing and using the SMIP compositions of the invention.
    Type: Application
    Filed: February 9, 2017
    Publication date: November 22, 2018
    Applicants: GlaxoSmithKline Biologicals SA, U.S. Army Medical Research and Materiel Command
    Inventors: Gillis OTTEN, Tom Yao-Hsiang WU, Travis K. WARREN, Sina BAVARI
  • THERMOSTABLE, CHROMATOGRAPHICALLY PURIFIED NANO-VLP VACCINE
    Publication number: 20170274063
    Abstract: In this application is described a method for preparing nano-VLP composition, thereby permitting purification using chromatography and filtration. The nano-VLP composition has a more uniform size range of filovirus particles, roughly 230 nm diameter, allowing ease of manipulation of the composition, while retaining GP conformational integrity and the antigenic effectiveness of the vaccine. Additionally, the nano-VLP can be lyophilized without loss of nano-VLP structure, or GP immunogenicity. Lyophilized nano-VLP have greatly enhanced thermostability, allowing the creation of a filovirus nano-VLP vaccine without a cold chain requirement.
    Type: Application
    Filed: August 7, 2015
    Publication date: September 28, 2017
    Applicant: THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF THE ARMY
    Inventors: John Howard Carra, Sina Bavari, David Hone
  • Benzonapthyridine compositions and uses thereof
    Patent number: 9597326
    Abstract: The present invention generally relates to compositions comprising benzonapthyridine small molecule immune potentiators (SMIPs) that are capable of stimulating or modulating an immune response in a subject that has had pre- or post-exposure to a pathogen such as hemorrhagic fever virus. Also provided are methods of preparing and using the SMIP compositions of the invention.
    Type: Grant
    Filed: April 13, 2011
    Date of Patent: March 21, 2017
    Assignees: GlaxoSmithKline Biologicals SA, U.S. Army Medical Research and Materiel Command
    Inventors: Gillis Otten, Tom Yao-Hsiang Wu, Travis K. Warren, Sina Bavari
  • Compositions and Methods for Inhibiting Expression of a Gene from the Ebola Virus
    Publication number: 20160264972
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a gene from the Ebola virus.
    Type: Application
    Filed: October 13, 2015
    Publication date: September 15, 2016
    Inventors: Sina Bavari, Kelly Lyn Warfield, Pamela Tan, Anna Borodovsky, Tatiana Novobrantseva, Antonin de Fougerolles
  • Fusion protein comprising the extracellular domain of a filovirus glycoprotein fused to an immunoglobulin heavy chain constant region
    Patent number: 9347951
    Abstract: This invention provides fusion proteins comprising a Filovirus glycoprotein segment and an immunoglobulin polypeptide segment. The fusion proteins are useful in immunogenic compositions to protect against infections by Filoviruses, such as Ebola virus, in both humans and non-human animals. The fusion proteins are also useful in diagnostic assays to detect Filovirus infections.
    Type: Grant
    Filed: October 28, 2011
    Date of Patent: May 24, 2016
    Assignee: THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH
    Inventors: Gerardo Kaplan, Krishnamurthy Konduru, Jerome Jacques, Sina Bavari, Steven Bradfute
  • FILOVIRUS FUSION PROTEINS AND THEIR USES
    Publication number: 20150346215
    Abstract: This invention provides fusion proteins comprising a Filovirus glycoprotein segment and an immunoglobulin polypeptide segment. The fusion proteins are useful in immunogenic compositions to protect against infections by Filoviruses, such as Ebola virus, in both humans and non-human animals. The fusion proteins are also useful in diagnostic assays to detect Filovirus infections.
    Type: Application
    Filed: May 5, 2015
    Publication date: December 3, 2015
    Inventors: Gerardo Kaplan, Krishnamurthy Konduru, Jerome Jacques, Sina Bavari, Steven Bradfute
  • Compositions and methods for inhibiting expression of a gene from the Ebola virus
    Patent number: 9187516
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a gene from the Ebola virus.
    Type: Grant
    Filed: May 15, 2014
    Date of Patent: November 17, 2015
    Assignees: Alnylam Pharmaceuticals, Inc., The United States of America, as Represented by the Secretary of the Army
    Inventors: Sina Bavari, Kelly Lyn Warfield, Pamela Tan, Anna Borodovsky, Tatiana Novobrantseva, Antonin de Fougerolles
  • Compositions And Methods For Inhibiting Expression Of CD45 Gene
    Publication number: 20150093417
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the CD45 gene.
    Type: Application
    Filed: December 2, 2014
    Publication date: April 2, 2015
    Inventors: Antonin de Fougerolles, Pamela Tan, Anna Borodovsky, Tatiana Novobrantseva, Sina Bavari, Kelly Lynn Warfield
  • Cleavage sensitive antibodies and methods of use thereof
    Patent number: 8936915
    Abstract: We disclose cleavage-sensitive antibodies with epitopes spanning the scissile bond of the toxins molecular target protein, enabling toxin-associated proteolysis to be measured in a variety of assay formats.
    Type: Grant
    Filed: August 17, 2010
    Date of Patent: January 20, 2015
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: Sina Bavari, Jonathan E. Nuss
  • Compositions and methods for inhibiting expression of CD45 gene
    Patent number: 8912316
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the CD45 gene.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: December 16, 2014
    Assignees: Alnylam Pharmaceuticals, Inc., The United States of America as represented by the Army
    Inventors: Antonin De Fougerolles, Pamela Tan, Anna Borodovsky, Tatiana Novobrantseva, Sina Bavari, Kelly Lyn Warfield
  • Compositions and Methods for Inhibiting Expression of a Gene from the Ebola Virus
    Publication number: 20140243394
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a gene from the Ebola virus.
    Type: Application
    Filed: May 15, 2014
    Publication date: August 28, 2014
    Applicants: Alnylam Pharmaceuticals Inc., The Government of the United States, as Represented by the Secretary of the Army
    Inventors: Sina Bavari, Kelly Lyn Warfield, Pamela Tan, Anna Borodovsky, Tatiana Novobrantseva, Antonin de Fougerolles
  • Compositions and methods for inhibiting expression of a gene from the Ebola virus
    Patent number: 8735369
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a gene from the Ebola virus.
    Type: Grant
    Filed: September 26, 2012
    Date of Patent: May 27, 2014
    Assignees: Alnylam Pharmaceuticals, Inc., The United States of America, as represented by the Secretary of the Army
    Inventors: Sina Bavari, Kelly Lyn Warfield, Pamela Tan, Anna Borodovsky, Tatiana Novobrantseva, Antonin de Fougerolles
  • Bacterial superantigen vaccines
    Patent number: 8710185
    Abstract: The present invention relates to genetically attenuated superantigen toxin vaccines altered such that superantigen attributes are absent, however the superantigen is effectively recognized and an appropriate immune response is produced. The attenuated superantigen toxins are shown to protect animals against challenge with wild type toxin. Methods of producing and using the altered superantigen toxins are described.
    Type: Grant
    Filed: November 28, 2011
    Date of Patent: April 29, 2014
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: Robert G. Ulrích, Mark A. Olson, Sina Bavari
  • Broad spectrum antibacterial compounds
    Patent number: 8691859
    Abstract: Disclosed herein are methods of inhibiting, reducing or preventing growth of or destroying bacteria of at least one bacterial strain which comprises contacting the bacteria with the compounds disclosed herein. Also disclosed are methods of treating, inhibiting or preventing an infection or intoxication caused by bacteria of at least one bacterial strain in a subject and pharmaceutical and cosmetic compositions comprising the compounds disclosed herein.
    Type: Grant
    Filed: August 11, 2006
    Date of Patent: April 8, 2014
    Assignee: The United States of America as Represented by the Secretary of the Army
    Inventors: Sina Bavari, Rekha G. Panchal, Rick Gussio
  • FILOVIRUS FUSION PROTEINS AND THEIR USES
    Publication number: 20130323243
    Abstract: This invention provides fusion proteins comprising a Filovirus glycoprotein segment and an immunoglobulin polypeptide segment. The fusion proteins are useful in immunogenic compositions to protect against infections by Filoviruses, such as Ebola virus, in both humans and non-human animals. The fusion proteins are also useful in diagnostic assays to detect Filovirus infections.
    Type: Application
    Filed: October 28, 2011
    Publication date: December 5, 2013
    Applicants: US ARMY MEDICAL RESEARCH AND MATERIEL COMMAND, The Government of the United States of America as Represented by the Secretary of The Dept of HHS
    Inventors: Gerardo Kaplan, Krishnamurthy Konduru, Jerome Jacques, Sina Bavari, Steven Bradfute
  • Compositions And Methods for Inhibiting Expression Of A Gene From the Ebola Virus
    Publication number: 20130225654
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a gene from the Ebola virus.
    Type: Application
    Filed: September 26, 2012
    Publication date: August 29, 2013
    Inventors: Sina Bavari, Kelly Lyn Warfield, Pamela Tan, Anna Borodovsky, Tatiana Novobrantseva, Antonin de Fougerolles
  • BENZONAPTHYRIDINE COMPOSITIONS AND USES THEREOF
    Publication number: 20130122042
    Abstract: The present invention generally relates to compositions comprising benzonapthyridine small molecule immune potentiators (SMIPs) that are capable of stimulating or modulating an immune response in a subject that has had pre- or post-exposure to a pathogen such as hemorrhagic fever virus. Also provided are methods of preparing and using the SMIP compositions of the invention.
    Type: Application
    Filed: April 13, 2011
    Publication date: May 16, 2013
    Applicants: Government of the United States, As Representing By the Secretary of the Army, IRM, LLC
    Inventors: Gillis Otten, Tom Yao-Hsiang Wu, Travis K. Warren, Sina Bavari
  • COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF CD45 GENE
    Publication number: 20130065943
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the CD45 gene.
    Type: Application
    Filed: September 12, 2012
    Publication date: March 14, 2013
    Inventors: Antonin De Fougerolles, Pamela Tan, Anna Borodovsky, Tatiana Novobrantseva, Sina Bavari, Kelly Lyn Warfield